Cartesian Therapeutics(NASDAQ) RNAC

Cartesian Therapeutics makes therapies to treat serious autoimmune diseases. These treatments help the body's immune system work correctly again. Patients can receive these medicines without staying overnight in a hospital.

What Cartesian Makes

• Descartes-08: Lead therapy candidate currently in Phase 3 trials for treating generalized myasthenia gravis, a muscle-weakening disorder.
• Descartes-15: Clinical-stage treatment designed to fight multiple myeloma, which is a type of bone marrow cancer.
• Autoimmune Pipeline: Experimental messenger RNA treatments targeting conditions like myositis and systemic lupus erythematosus in various development stages.
• Proprietary Platform: Specialized technology that introduces messenger RNA into cells to produce a specific therapeutic effect.

Strategic Moves and New Funding

• Secured a senior secured term loan facility for up to $150.0 million from K2 HealthVentures LLC in May 2026.
• Entered into a license agreement with WestGene Biopharma Co., Ltd. in June 2026 to develop new cell therapies.
• Signed a worldwide patent license agreement with Biogen MA, Inc. in Sept. 2023 for specific T-cell sequences.
• Formed a development agreement with Swedish Orphan Biovitrum AB in June 2020 for a chronic refractory gout treatment.
• Raised $19.3 million in net proceeds through an equity offering program during the first half of 2026.

How the Technology Works

Cartesian uses messenger RNA to create cell therapies that can be administered in an outpatient setting without requiring chemotherapy. Because the messenger RNA degrades naturally over time, these treatments can be given to patients repeatedly like traditional drugs.

Important Financial Figures

• Net loss was $23.4 million for the six-month period ended June 30, 2026, compared to a net loss of $1.8 million in the prior year.
• Research and development expenses were $39.9 million for the six months ended June 30, 2026, up 35% year over year.
• Total revenue was $78,000 for the six-month period ended June 30, 2026, down 94% year over year.
• Cash, cash equivalents, and restricted cash reached $149.3 million as of June 30, 2026.
• Market capitalization was $307.0 million for the quarter ended June 30, 2026, up 13.7% year over year.

Bottom Line

Cartesian has transitioned from early research to late-stage clinical development of messenger RNA-based cell therapies. The company maintains its focus on expanding its pipeline through internal manufacturing and strategic licensing agreements.